Study #2025-0072
A phase 3, multicenter, double-blind, placebo-controlled study assessing the efficacy and safety of Olomorasib in combination with standard of care immunotherapy in participants with resected or unresectable KRAS G12C-mutant, non-small cell lung cancer - SUNRAY-02
MD Anderson Study Status
Enrolling
Treatment Agent
Olomorasib, Pembrolizumab, Placebo, Durvalumab
Description
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Carcinoma, Non-Small-Cell Lung
Study phase:
Phase III
Physician name:
Marcelo Vailati Negrao
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.